These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25520957)

  • 1. Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg.
    Nguyen TP; Biliciler S; Wahed A; Sheikh K
    Neurol Neuroimmunol Neuroinflamm; 2014 Dec; 1(4):e50. PubMed ID: 25520957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis.
    Zaki HA; Iftikhar H; Najam M; Masood M; Al-Marri NDR; Elgassim MAM; Fayed M; Shaban EE
    eNeurologicalSci; 2023 Jun; 31():100468. PubMed ID: 37288440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
    Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
    No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease.
    Van Anh KY; Shah S; Tremoulet AH
    Front Pediatr; 2020; 8():146. PubMed ID: 32318529
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?
    Godoy DA; Rabinstein A
    Arq Neuropsiquiatr; 2015 Oct; 73(10):848-51. PubMed ID: 26465402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autoimmune neuropathies: diagnosis, treatment, and recent topics].
    Ueda M; Kusunoki S
    Brain Nerve; 2011 Jun; 63(6):549-55. PubMed ID: 21613658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.
    Ucar İ; Koyuncu MB; Solmaz AA; Ugurludogan AC; Mercan S; Kucuk M; Unal T; Mazman S; Atilla E
    Transfus Clin Biol; 2023 Feb; 30(1):11-15. PubMed ID: 36028153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
    Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
    Indian J Med Res; 2003 May; 117():216-20. PubMed ID: 14609050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
    Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apheresis therapy in Guillain-Barré syndrome].
    Nagayama H; Katayama Y
    Nihon Rinsho; 2008 Jun; 66(6):1195-9. PubMed ID: 18540370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study.
    Islam MB; Islam Z; Rahman S; Endtz HP; Vos MC; van der Jagt M; van Doorn PA; Jacobs BC; Mohammad QD
    Pilot Feasibility Stud; 2017; 3():40. PubMed ID: 28975040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.